Kamalika Mazumder

Kamalika Mazumder

Auto-generated profile, based on publicly available information

Kamalika Mazumder

B.C.D.A. College of Pharmacy & Technology

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2025 in Infectious Disorders - Drug Targets
Verified
Journal Article
Closed access
PDF file
DBDebolina Banerjee
Debolina Banerjee
PBPoulomi Biswas
Poulomi Biswas
KMKamalika Mazumder
Kamalika Mazumder
SPSangita Palai
Sangita Palai
CHChowdhury Mobaswar Hossain
Chowdhury Mobaswar Hossain
KBKaushik Biswas
Kaushik Biswas
Multicellular surface-attached populations of bacteria embedded in the extracellular matrix are known as biofilms. Bacteria generally preferred to grow as biofilms. Quorum sensing (QS), detection of density of cell population through gene regulation, has been found to play an important role in the production of biofilms. Biofilm formation can increase the severity of infections that can lead to morbidity or mortality. Bacteria living within biofilms have a higher pattern of adaptive resistance to antibiotics. Antibiotic resistance is a barrier in the treatment of biofilmsinduced acute to chronic infections such as post-surgery infections, surgery-associated wound infections, endocarditis, joint infections, burn-related wound infections occurred, ventilator-associated pneumonia, etc. So it is urgent to discover or find out potent new drugs in fight against infectious diseases such as biofilms-associated infections. Medicinal plants or herbs are a rich source for fighting with biofilms-mediated infections. Phytochemicals have exhibited significant effects in the prevention of biofilms formation against different bacteria that are causing infections. Purified compounds such as berberine, tetrandrine, embelin, xanthorrhizol, bakuchiol, etc., exhibited promising biofilm inhibition actions against different pathogenic bacteria. Plant extracts that contain several phytochemicals are evaluated for its biofilm’s inhibition property, and have shown significant potential in biofilm formation. Antibiofilm agents act by distinct mechanisms such as inhibiting the adherence of biofilms in a surface, preventing the biofilm formations, disrupting the matured biofilms, etc. This study is intended to reiterate about possibilities of plant extracts and purified compounds in the treatment of the prevention of bacterial biofilms-related infections.

10 October 2025 in Chemistry & Biodiversity
Verified
Journal Article
Closed access
PPPankaj Paul
Pankaj Paul
SDSandip Dolui
Sandip Dolui
SISumee Ireen
Sumee Ireen
SBSubhadip Bisoi
Subhadip Bisoi
SPSangita Palai
Sangita Palai
KBKaushik Biswas
Kaushik Biswas

5 July 2026 in Future Microbiology
Verified
Journal Article
Closed access
SRSomnath Roy
Somnath Roy
PPPankaj Paul
Pankaj Paul
RSRuchita Santra
Ruchita Santra
SDSandip Dolui
Sandip Dolui
APAritra Pramanik
Aritra Pramanik
KBKaushik Biswas
Kaushik Biswas
To explore the mechanism involved in the inhibition of biofilm formation and antibacterial action of endophytic Streptomyces sp. isolated from the Indian Sundarbans Mangrove Forest. In this study, Streptomyces sp. KJ7TB2 was isolated from the Indian Sundarbans. An ethyl acetate extract was subjected for GC-MS profiling. The mechanisms of antibacterial and antibiofilm action were also explored. In-silico molecular docking and dynamics simulation analyses were performed. The GC-MS analysis of the extract revealed 14 distinct bioactive secondary metabolites. The extract exhibited potent MIC values of 250 μg/mL and 125 μg/mL against Escherichia coli MTCC 1195 and Pseudomonas aeruginosa ATCC 27853. Antibiofilm investigation further revealed inhibition of biofilm formation in both pathogens especially in E. coli MTCC 1195, likely by disrupting initial surface adhesion and exopolysaccharide synthesis. Also, the extract inhibited swarming motility, suggesting interference with flagella-driven motility and quorum sensing. The brine shrimp lethality assay confirmed a favorable safety profile, recording limited mortality (36.84% at 2×MIC over 24 h). In-silico molecular docking and dynamics simulation analyses exhibited robust affinity for two key biofilm-associated proteins, exhibiting significant binding energy (ΔG). The study highlights Streptomyces sp. KJ7TB2 as a potential source for the discovery of safe, potent therapeutics.

7 December 2020 in Asian Journal of Chemistry
Verified
Journal Article
Open access
PCPriyanka Chakraborty
Priyanka Chakraborty
KMKamalika Mazumder
Kamalika Mazumder
NBNripendra Nath Bala
Nripendra Nath Bala
SDSudipta Das
Sudipta Das
Present study was focused on the isolation and characterization of the anti-inflammatory compound(s) from the methanolic extracts of Arisaema tortuosum tuber by column chromatography, TLC, FT-IR, 1H, 13C NMR and HR-MS. Among all the fractions obtained A. tortuosum fraction 3 (PC-1) and fraction 5 (PC-2) showed significant in vivo anti-inflammatory activity. This study endorsed that the isolated bioactive compound PC-2 showed better anti-inflammatory activity at a dose of 25 mg/Kg BW. The results indicate that PC-2 and PC-1 methanolic extract of A. tortuosum tuber may be competing for the tent in the therapy of inflammatory ailments.

12 May 2026 in Current Drug Research Reviews
Verified
Journal Article
Closed access
PDF file
PKPritam Kamila
Pritam Kamila
Koyel KarKoyel Kar
Koyel Kar
SCSailee Chowdhury
Sailee Chowdhury
KMKamalika Mazumder
Kamalika Mazumder
PCPriyanka Chakraborty
Priyanka Chakraborty
TPTapash Pramanik
Tapash Pramanik
Introduction: Migraine and cluster headaches are common primary headache disorders that substantially impair quality of life and increase healthcare burden. Treatment efficacy is often limited by variability in patient response, partly due to genetic factors. This review examines current acute and preventive therapies for migraine, with a focus on the influence of genetic variations. Methods: A literature review was performed on migraine pathophysiology, highlighting the trigeminovascular system and genetic contributions, particularly in familial hemiplegic migraine. Pharmacological interventions assessed included triptans, NSAIDs, anticonvulsants, antidepressants, calcium channel blockers, and emerging agents such as CGRP-targeted antibodies, gepants, and relaxants. The impact of genetic variations on drug efficacy, metabolism, and safety was also evaluated. Results: Genetic mutations affect both migraine susceptibility and therapeutic response. Triptans and NSAIDs remain first-line acute treatments, whereas anticonvulsants, antidepressants, and calcium channel blockers are commonly used for prophylaxis. Emerging CGRP-targeted therapies and gepants provide effective alternatives for patients with inadequate responses to conventional therapies. Genetic polymorphisms may modify pharmacokinetics and pharmacodynamics, supporting personalized treatment strategies. Discussion: The interconnection between genetics and pharmacological response underscores the importance of individualized treatment. While traditional therapies remain effective for many years, emerging agents provide options for refractory cases. Understanding genetic contributions can guide therapy selection, optimize efficacy, and minimize adverse effects. Conclusion: Migraine management relies on traditional pharmacological agents alongside emerging therapies targeting CGRP pathways. Genetic variations significantly influence disease susceptibility, treatment response, and safety. Integrating genetic insights into clinical practice can optimize therapeutic outcomes and advance personalized management strategies for patients with primary headache disorders.